- Home
- VRCA vs IGI Comparison
VRCA vs IGI Comparison
Compare VRCA & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VRCA | IGI |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 96.2M |
| IPO Year | 2018 | 2009 |
Fundamental Metrics
Financial Performance| Metric | VRCA | IGI |
|---|---|---|
| Price | $5.53 | $15.98 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 108.5K | 24.1K |
| Earning Date | 03-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $103.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.39 | $15.70 |
| 52 Week High | $9.82 | $17.09 |
Technical Indicators
Market Signals| Indicator | VRCA | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 25.44 |
| Support Level | $5.18 | $15.78 |
| Resistance Level | $6.48 | $16.62 |
| Average True Range (ATR) | 0.53 | 0.14 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 26.60 | 1.92 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.